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Summary Murine L5178Y-ML cells, when transplanted subcutaneously into the flank of (BALB/c x DBA/
2)F, mice, grew locally and always formed spontaneous metastases in the liver. Even after surgical removal of
the primary tumour mass 5 or 7 days after tumour cell inoculation, all mice died due to liver metastases within
18 days. Using this model of tumour metastasis, we examined whether serine protease or deoxyribonuclease I
(DNase I) would affect metastasis. Spontaneous liver metastasis of L5178Y-ML cells was enhanced by
systemic administration of a-chymotrypsin at 3, 4 and 5 days or at 5, 6 and 7 days after tumour cell
inoculation. This result was consistent with a previous report on blood-borne lung metastasis. In contrast,
systemic administration of DNase I at 3, 4 and 5 days or at 5, 6 and 7 days after tumour cell inoculation
inhibited liver metastasis. Neither treatment affected primary tumour growth. An influence of DNase I on
tumour cell arrest in the microvasculature of the liver was suggested by scanning electrom microscopy. DNase
I treatment resulted in a statistically significant prolongation of the survival period, however, the effect was not
satisfactory. A more striking anti-metastatic treatment resulting in a greater prolongation of the survival
period was achieved by combining surgical removal of the primary tumour mass with DNase I treatment.
These results suggest that DNase I could be a potential therapeutic agent used in conjunction with surgery to
prevent clinical blood-borne metastasis.
The process of metastasis is complicated, involving release of
cells from a primary tumour, dissemination to distant sites,
arrest in the microcirculation in other organs, and infiltration
into these organs and growth in secondary sites (Fidler et al.,
1978; Roos & Dingemans, 1979; Poste & Fidler, 1980). Fidler
(1973) originally demonstrated the importance of cluster for-
mation of circulating tumour cells in metastasis using B16
melanoma cells in mice. It has also been shown that an
important event in blood-borne metastasis is intercellular
adhesion and aggregation of circulating tumour cells (Nicol-
son & Winkelhake, 1975).
We have found that serine proteases such as a-
chymotrypsin or elastase caused tumour cell aggregation in
vitro and enhanced blood-borne lung metastasis in vivo in the
rat ascites tumour cell lines, AH-130, AH-109A and YS.
Deoxyribonuclease I (DNase I) dispersed the tumour cell
aggregates and reduced the lung metastasis (Sugihara et al.,
1990). We also observed that these alterations in frequency of
metastasis were direct reflections of changes of sequestration
intensity in the lungs of the tumour cells, probably due to
aggregation and disaggregation in vivo (Sugihara et al., sub-
mitted for publication). Our electron microscopic study
showed that this aggregation seemed to be caused by forma-
tion of a sleeve-like structure which surrounded the cells and
connected them with each other. This structure probably
originated from the cell surface glycocalyx in some sort of
association with DNA molecules (Sugihara et al., 1991).
Protease treatment and DNase I treatment clearly altered the
metastatic rate in the blood-borne lung colonisation model.
However, this model in which large numbers of tumour cells
are injected intravenously bears little resemblance to clinical
blood-borne metastasis.
Recently we examined a spontaneous metastasis model in
mice using the L5178Y-ML cell line established by Watanabe
and his co-workers (Watanabe et al., 1988). The L5178Y-ML
cell line was derived from L5178Y, a murine T-lymphoma
cell line isolated from a methylcholanthrene-induced lym-
phoma in DBA/2 mice. In order to establish a liver-oriented
metastatic tumour cell line, cells were propagated further
sequential cycles of subcutaneous inoculation of L5178Y cells
which were isolated from the metastatic liver masses.
L5178Y-ML cells, therefore, metastasised predominantly to
the liver after intravenous or subcutaneous injection
(Watanabe et al., 1988). In our preliminary study. L5178Y-
ML cells were also sensitive to serine proteases and to DNase
I in tumour cell aggregation and disaggregation, respectively.
The present study was, therefore, undertaken to confirm the
effects of protease and nuclease in altering the blood-borne




Female BALB/c x DBA/2 (CDF,) mice were obtained from
Shizuoka Agricultural Cooperative Association for
Laboratory Animals (Hamamatsu, Japan). These mice
received a standard mouse chow and tap water ad lib. They
were 6 to 8 weeks old at beginning of each experiment.
Reagents
Crystallised bovine pancreatic a-chymotrypsin and bovine
pancreatic DNase I were purchased from Sigma Chem. Co.,
St. Louis, Mo.
Tumour cells
The murine tumour cell line, L5178Y-ML, was obtained
from Dr Okura of the Exploratory Research Laboratories,
Banyu Pharmaceutical Co., Ltd., Tokyo. This line was main-
tained in vitro in RPMI-1640 medium supplemented with
10% foetal calf serum and antibiotics according to the
method of Watanabe et al. (1988).
Generalprocedurefor study ofspontaneous metastasis
Suspensions of L5178Y-ML cells in RPMI-1640 at I07cells
ml-' possessed the viability of more than 97% as measured
by the trypan blue dye exclusion test. In the tumour cell
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inoculation 1 x 106 cells were subcutaneously implanted into
the flank of mice. On day 12, the animals were killed under
ether anaesthesia, and the livers resected and weighed.
Because of the good correspondence between the numbers of
tumour cells in the liver and the increase in liver weight
(Watanabe et al., 1988), we usually measured the liver weight
to evaluate the intensity of metastasis in the liver. The
volume of tumour grown at the initial inoculation site was
measured in volume from the formula, (L x W2)/2, where
L = length (mm) and W = width (mm).
Systemic treatment by intravenous enzyme injection
In in vivo experiments using the protease, one group of
tumour-bearing mice received intravenous injections of a-
chymotrypsin (1.0 mg per mouse) at days 3, 4 and 5 after
tumour cell inoculation and another group received the same
treatment at days 5, 6 and 7. In the control groups, 0.1 ml of
phosphate buffered saline (PBS) was intravenously injected at
days 3, 4 and 5 or at days 5, 6 and 7 after tumour cell
inoculation. In experiments with DNase I, DNase I (0.1 U
per mouse) was injected into two groups of mice using the
same schedules as above. The effects of the protease or the
nuclease were evaluated by measuring liver weight.
Surgical removal ofsubcutaneous tumours
In studies on effects of the enzyme treatments on mortality,
L5178Y-ML cells (1 x 106 per mouse) were subcutaneously
inoculated in the usual manner. On day 7, however, the
primary tumour mass was excised surgically under ether
anaesthesia, and the wound was closed with silk threads. The
size of the removed mass was measured. Alpha-chymotrypsin
(1.0 mg/mouse/day) or DNase I (0.1 U/mouse/day) was int-
ravenously injected for 3 days either before or after primary
tumour removal, and the survival periods were compared.
Autopsies were performed in all mice.
Histological examination
For light microscopic examination, small pieces of tissues
were fixed with 10% formalin and embedded in paraffin in
usual ways. The tissue specimens sliced were stained with
hematoxylin and eosin.
For scanning electron microscopy, the liver was fixed with
a perfusion method. Under pentobarbital anaesthesia,
0.1 MPBS containing heparin (1 IUg-' animal weight) was
intravenously injected into the tail vein and the thoraco-
abdominal cavity was surgically opened. The left ventricle
was cannulated for systemic perfusion with 3%
glutaraldehyde in 0.1 MPBS at room temperature, and the
right atrium was cut for drainage. The perfused liver was
removed and cut into pieces approximately 2 mm in thick-
ness, and fixed in 1% osmium tetroxide in 0.1 MPBS. After
dehydration using graded series of ethanol, the fixed tissues
were subjected to frozen liquid cracking (Hamano et al.,
1973). The tissues were then dried using the t-butyl alcohol
freeze-drying method (Inoue & Osatake, 1988), and the
cracked surface was coated by platinum-paladium and
viewed in a scanning electron microscope (JSM-6400FK)
with an accelerating voltage of 20kV.
Statistical analysis
Differences in liver weight were compared by the com-
puterised, non-parametric, Mann-Whitney U-test. Survival
comparisons between groups were tested for significance by
the Kaplan-Meier method.
Results
Spontaneous metastasis ofL5178Y-ML cells to the liver
In all mice implanted with L5178Y-ML cells, a tumour mass
developed which became macroscopically recognisable at day
5. After 12 days, the animals were killed under ether
anaethesia and visceral organs including the liver, lungs,
kidneys and spleen were examined macroscopically and his-
tologically. In all cases, severe metastasis in the liver but in
no other organs was observed. As shown in Table I, the
mean weight of the liver in the tumour-bearing mice was
2.27 ± 0.14 g, which was 2.7 fold heavier than that in the
normal mice (0.85 ± 0.08 g). The mean size of the primary
tumour mass at day 12 was 5,229 ± 441 mm3. Since the liver
metastasis was quite reproducible and the frequency was
easily evaluated, this system is useful as a spontaneous cancer
metastasis model.
Effects ofprotease and nuclease treatments on liver metastases
ofL5178Y-ML cells
We initially speculated that there might be a critical time
period in the metastasis and that enzyme treatments might
have to be targeted to such a period. When CDF1 mice were
subcutaneously inocluated with 1 x 106 L5178Y-ML cells and
the primary tumour mass was surgically resected on day 5,
all the mice died by day 15 due to the liver metastasis,
indicating that micrometastasis had already started by day 5.
We, therefore, divided the inoculated animals into six groups.
Three groups were treated intravenously from day 3 to day 5
with a-chymotrypsin (1.0 mg/injection), DNase I (0.1 U/
injection) or PBS, and the remaining three groups were
treated similarly from day 5 to day 7. All animals were
sacrificed on day 14 and the liver weight and the sub-
cutaneous tumour size were measured.
There was, however, no difference between the groups
treated at different times (Table II). There were, however,
significant statistical differences between the different treat-
ment. Alpha-chymotrypsin treatment increased liver weight
from 2.26 to 2.92 g, whereas DNase I treatment reduced it to
1.55 g. In contrast, neither x-chymotrypsin nor DNase I
affected tumour growth at the original site. The results
indicated that both a-chymotrypsin and DNase I affected the
intensity of liver metastasis.
Histological observation on liver metastases
Light microscopy revealed a wide variation in the size of the
foci of tumour metastasis in the enlarged liver in the group
treated with PBS (Figure la). The x-chymotrypsin-treated
group (Figure lb) showed diffuse infiltration of L5178Y-ML
cells and severe centrilobular necrosis, a few liver cells
remaining among the metastatic foci. In contrast, in the
DNase I-treated group (Figure lc, ld), the numbers of
metastatic foci were fewer and their sizes smaller. The
Table I Primary tumour growth and liver metastasis of
L5178Y-ML cells
Mean liver weight (g) Primary tumour size (mm3)
Normal 0.81 ± 0.09
Tumour bearing 2.27 ± 0.14a 5,229 ± 441
Each value is the mean ± s.d. ap <0.01. n = 6 in each group.
Table II Effects of a-chymotrypsin and DNase I treatment on liver
metastases of L5178Y-ML cells
Treatment Liver weight (g) Primary tumour size (mm)
On days 3, 4 and 5
PBS 2.26 0.13 5,229 441
a-chymotrypsin 2.92 + 0.16a 5,186 + 357
DNase I 1.55 0.21a 4,992 296
On days 5, 6 and 7
PBS 2.33 0.14 4,948 194
a-chymotrypsin 2.92 ± 0.10a 4,800 ± 542
DNase I 1.68 0.12a 5,035 644





Figure 1 Light micrographs of the liver of the mice on day 12 after subcutaneous inoculation of L5178Y-ML cells. a, PBS-treated
control. Hepatocytes are mostly replaced by tumour cells. b, a-chymotrypsin-treated case. Severe intralobular necrosis can be seen.
Diffuse and focal tumour metastases are present around the vessels and in the sinusoids. c, DNase I-treated case. In rare cases, a
few tumour cell foci can be seen in the liver tissue. d, DNase I-treated case. In usual cases, no tumour cells is scattered in the liver
tissue. Scale bar = 1I00 tm.
tumour cell colonies were sometimes present around the
vessels and sinusoids. Micrometastases were not found in the
spleen, lungs or kidneys. Results from light microscopy were
in accord with the results of liver weight after enzyme treat-
ment.
To elucidate the mechanism of DNase I in preventing liver
metastasis, we attempted to observe arrest of tumour cells in
the microvasculature of the liver 10 days after cutaneous
inoculation by scanning electron microscopy with the freezed
fracture technique. As shown in Figure 2, tumour cells
attached to endothelial cells of the pre-sinusoidal portal vein
in groups. The number of cell groups as well as the number
of cells in each group was significantly less after DNase I
treatment. After treatment with PBS, structures of a mesh- or
cloth-like shape, which surrounded the tumour cells on
endothelial cells, were occasionally seen. These structures
were rarely seen after DNase I treatment. In no case was
endothelial cell damage seen. These observations suggested
an effect of DNase I treatment on tumour cell arrest.
Effect ofprotease or nuclease on mortality ofmice implanted
with L5178Y-ML cells
All the tumour-bearing control mice treated with PBS died
within 18 days after subcutaneous tumour implantation. As
shown in Figure 3, while o-chymotrypsin treatment had no
significant effect on survival period, DNase I treatment pro-
longed the survival period up to 24 days. The same experi-
ment was carried out three times, and similar results were
obtained. Although the prolongation was statistically
significant, the effect was not satisfactory. We speculated that
because of the presence of the primary tumour mass, tumour
cells might have a chance to metastasise to the liver after
disappearance of the intravenously injected DNase I.
Therefore, in the next experiment, we examined the effect of
DNase I treatment on the mortality of mice in combination
with surgical resection of the primary tumour mass. When
the primary tumour mass was resected on day 7, significant
prolongation of survival was achieved in the DNase I group
treated on days 5, 6 and 7 after tumour cell inoculation
compared to the untreated group (P<0.01, Figure 4). This
experiment was repeated twice with similar results. However,
the increase in survival period was less when the DNase I
treatment was carried out on days 8, 9 and 10 after tumour
cell inoculation. Autopsies revealed marked liver metastases
which were the cause of death in every animal.
Discussion
The augmenting and reducing effects of a-chymotrypsin and
DNase I on blood-borne metastasis were originally demon-
strated in a rat model in which metastatic foci were produced
in the lung by injecting the tumour cells intravenously
(Sugihara et al., 1990). However, this experiment is open to
criticism in that the introduction of so many tumour cells
into the circulation at once seems unlikely under clinical
conditions. The present confirmatory results on the effects of
these enzymes in the clinically more realistic L5178Y-ML
metastatic model are therefore important.
From the clinical sense in regard to tumour therapy, the
effect of DNase I on reducing the metastatic rate from the
b
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Figure 2 Scanning electron micrographs of the liver of the mice on day 10 after subcutaneous inoculation of L5178Y-ML cells. a,
PBS-treated control. Many tumour cells arrested on endothelial cells. b, DNase I-treated case. Number of tumour cells is
significantly smaller than the control. Endothelial cells are intact. Scale bar = 10pm.
initial cutaneous mass to the liver is more interesting than the
effect ofoc-chymotrypsin. The inhibitory effect of DNase I on
tumour metastasis has also been reported by Salganik et al
(1967) who demonstrated reduction of leukaemic cell metas-
tasis in AKR mice by treatment with repetitive int-
raperitoneal DNase injection.
In the present investigation, DNase I administration into
the tail vein at 3 to 5 days or at 5 to 7 days after the
subcutaneous tumour inoculation caused potent inhibition of
liver metastasis (Table II). DNase I administration did not
affect the growth of the subcutaneous tumours. In addition,
the failure of primary tumour resection at 5 days to prevent
liver metastasis indicated the presence of tumour cells with
metastatic potency in the circulation at least 5 days after
subcutaneous tumour cell inoculation. These results indicated
that DNase I interfered with tumour cells in the circulation.
How DNase I interferes with tumour cells is not yet clear.
Our observations with the scanning electron microscope sug-
gested that the prevention of metastasis might be a conse-
quence of the reduction of tumour cell arrest in the microvas-
culature in the liver. In association with this reduction of
arrest, the number of mesh- or cloth-shape structures, which
surrounded the arrested tumour cells, decreased. Destruction
of similar structures, which were composed of DNA, has
been previously observed in vitro, when tumour cell agg-
regates were treated with DNase I to cause disaggregation
(Sugihara et al., 1991).
Therefore, the effect of DNase I on reducing metastasis
might relate to this disaggregation. In the previous experi-
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Figure 3 Effects of protease or nuclease on mortality of CDF1
mice bearing L5178Y-ML cell tumour. Animals were divided into
five groups (n = 5 in each group) and treated as follows; int-
ravenously injected with 1.0 mg a-chymotrypsin per mouse on
days 3, 4 and 5 (0), or on days 5, 6 and 7 (l), or with 0.1 U
DNase I per mouse on days 3, 4 and 5 (0), or on days 5, 6, 7
(l) or with PBS (A).
tasis, and in this model, it inhibited liver metastasis. The
effect of DNA in causing or enhancing blood-borne metas-
tasis does not, therefore, seem to be organ specific. On the
other hand, it is known that occurrence of metastases of the
L5178Y-ML cells following intravenous or subcutaneous
inoculation is almost solely in the liver (Watanabe et al.,
1988). This liver specificity was again demonstrated in the
present study. We speculated the liver specific arrest of
tumour cells might be mediated basically by specific intercel-
lular adhesion molecules on the tumour cells and on the
endothelial cells of liver microvasculature. This type of
interaction might, however, be easily prevented by shear
stress of the circulation, and might require some predisposing
phenomena such as intercellular aggregation of tumour cells
or formation of tumour emboli. The effect of DNA might be
to cause such aggregation of tumour cells. The source of the
DNA is probably chromatin of tumour cells which have been
destroyed in the circulation, since it has been reported that
most of the tumour cells injected in the circulation were
initially arrested in capillary beds, only a few (0.1%) surviv-
ing to develop into colonies (Fidler, 1970).
o 20406
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Figure 4 Effects of the protease or nuclease treatment in con-
junction with tumour resection on mortality of CDF, mice
inoculated with L5178Y-ML cells. The primary tumour mass was
surgically removed on the 7th day after the tumour cell inocula-
tion. Animals were divided into five groups (n= 5 in each group)
and treated as follows; intravenously injected with either PBS
(A), 1.0 mg a-chymotrypsin per mouse on days 5, 6 and 7 (0),
or on days 8, 9 and 10 (A), or 0.1 U DNase I per mouse on days
5, 6 and 7 (0), or on days 8, 9 and 10 (U).
The most important result of the present study must be the
life span-prolongation effect of DNase I in combination with
surgical treatment of the primary lesion. Surgical removal of
the subcutaneously inoculated tumour alone had no prolong-
ing effect and all mice died from micrometastases in early
periods. Many combinations of DNase I treatment with
other tumour therapies are possible. Thus, DNase I treat-
ment may be potentially useful in the prevention of cancer
metastasis, though further detailed work is required.
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